Endocrine therapy, including selective estrogen receptor modulators (SERMs) like tamoxifen and selective estrogen receptor degraders (SERDs) such as fulvestrant, is standard treatment for treating estrogen receptor‐positive (ER+) breast cancer [98]. Here, ESR1 is linked to breast cancer.